Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
Related Research units
Abstract
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
Bibliographical data
Original language | English |
---|---|
ISSN | 0022-1899 |
DOIs | |
Publication status | Published - 31.08.2023 |
Comment Deanary
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PubMed | 36857443 |
---|